ALBERT

Description: Among chemotherapeutic agents, cisplatin and the other platinum-based drugs have occupied for 35 years an enviable position. The limitations of platinum-based drugs, dose dependent side effects and development of drug resistance mechanisms, have boosted the research for finding other metal-based drugs. Among metals, ruthenium is probably the one showing the greatest promises. Ruthenium (Ru) appears to be less toxic than platinum and several biological studies have indicated that ruthenium complexes possess diverse modes of action. The redox chemistry of ruthenium is rich and compatible with biological media, and the overall toxicity of ruthenium is lower than platinum, thus allowing higher doses of treatment. In this study we aimed that, analyses of different type of ruthenium complexes in cancer cell lines. Six Ru complexes were determined by elemental analysis, FTIR, NMR, UV-visible spectroscopy, electron density on the metal was measured by cyclic voltammetry. After that, the cellular properties of this complexes were analyses on PC-3, HT-29, Du-145 and Vero cell lines. DNA damage was analyzed H2AX staining, apoptotic cell analyses were performed flow cytometry and western blotting. After 48 h incubation of Ru complexes three of them more effective for cell lines. Especially Ru3 was more effective in cancer cell lines. Apoptotic pathway was triggered after Ru complexes incubation in PC-3, Du-145 and Ht-29 cancer cell lines. Our study suggest that Ru complexes may be used for cancer cell cytotoxicity as a drugs in patients.